Ocular Therapeutix? Announces Topline Results for Phase 2 Clinical Trial of OTX-CSI for the Treatment of Dry Eye Disease Did Not Meet Primary Endpoint
Ocular Therapeutix, Inc. announced topline results from its Phase 2 clinical trial of OTX-CSI for the treatment of dry eye disease . The Phase 2, U.S.-based, randomized, double-masked, multi-center,... | October 23, 2021